Dr. Madan is a Senior Clinician at the National Cancer Institute (NCI), conducting clinical research in prostate cancer with a focus on immunotherapy strategies. Dr. Madan received his M.D. from the UMDNJ-New Jersey Medical School in 2001 and completed his internal medicine residency at UMDNJ-University Hospital in June 2004. He joined the NCI Medical Oncology Branch as an oncology/hematology fellow in 2005. In 2009 he was retained on staff as an assistant clinical investigator. In 2014 he was made the clinical director of the Genitourinary Malignancies Branch and in 2018 he became a Senior Clinician. He holds a joint appointment in the Laboratory of Tumor Immunology and Biology which forms the basis for many of his clinical collaborations. His research interests are focused on immune stimulating therapeutic cancer vaccines and novel therapies in the treatment of prostate cancer.
- Madan RA, Gulley JL. (R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment. J Natl Cancer Inst. 2015;107(1):347.
- Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol. 2012;39(3):296-304.
- Madan RA, Heery CR, Gulley JL. Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. Oncoimmunology. 2012;1(7):1167-1168.
- Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):501-8.
- Madan RA, Arlen PM, Gulley JL. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther. 2007;7(4):543-54.
Related Scientific Focus Areas
This page was last updated on Friday, September 23, 2022